Anna M Blom Selected Research

Complement System Proteins (Complement)

1/2022	The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity.
12/2021	Clinical characterization and identification of rare genetic variants in atypical hemolytic uremic syndrome: A Swedish retrospective observational study.
1/2021	The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.
1/2021	Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE.
1/2021	Functional Analysis of Variants in Complement Factor I Identified in Age-Related Macular Degeneration and Atypical Hemolytic Uremic Syndrome.
11/2020	Effect of rare coding variants in the CFI gene on Factor I expression levels.
1/2020	Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q.
1/2020	Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
1/2020	A soft tick Ornithodoros moubata salivary protein OmCI is a potent inhibitor to prevent avian complement activation.
1/2020	Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna M Blom Research Topics

Disease

24	Inflammation (Inflammations) 01/2022 - 09/2005
17	Neoplasms (Cancer) 08/2021 - 01/2005
16	Rheumatoid Arthritis 01/2020 - 01/2007
15	Infections 12/2019 - 05/2005
12	Atypical Hemolytic Uremic Syndrome 12/2021 - 03/2007
10	Breast Neoplasms (Breast Cancer) 11/2021 - 01/2013
8	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2016 - 02/2010
7	Macular Degeneration (Age-Related Maculopathy) 01/2021 - 04/2007
7	Arthritis (Polyarthritis) 01/2018 - 09/2006
6	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 08/2011
6	Joint Diseases (Joint Disease) 01/2013 - 09/2005
5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2012
5	Glomerulonephritis 01/2019 - 08/2011
3	Lyme Disease (Disease, Lyme) 01/2022 - 03/2010
3	Gonorrhea 01/2021 - 11/2005
3	Hemolysis 01/2021 - 08/2009
3	Lupus Nephritis 01/2020 - 12/2017
3	Lymphoma (Lymphomas) 01/2020 - 11/2007
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 12/2013
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 08/2008
3	Rheumatic Diseases (Rheumatism) 09/2017 - 08/2012
3	Osteoarthritis 10/2016 - 01/2012
3	Thrombosis (Thrombus) 10/2015 - 08/2012
3	Scabies (Sarcoptic Mange) 05/2014 - 06/2009
3	Kaposi Sarcoma (Kaposi's Sarcoma) 02/2011 - 01/2007
2	Hyperglycemia 01/2022 - 01/2017
2	Proteinuria 01/2020 - 01/2019
2	Pancreatitis 01/2020 - 09/2005
2	Kidney Diseases (Kidney Disease) 01/2019 - 01/2011
2	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2008
2	Bacterial Infections (Bacterial Infection) 12/2017 - 07/2015
2	Systemic Scleroderma (Systemic Sclerosis) 11/2016 - 01/2013
2	Necrosis 10/2016 - 06/2004
2	Wounds and Injuries (Trauma) 10/2016 - 04/2012
2	Nephritis 09/2014 - 01/2011
2	Acquired Immunodeficiency Syndrome (AIDS) 03/2013 - 04/2006
2	Myocardial Infarction 12/2011 - 08/2008
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2009 - 01/2008
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2022
1	Lymphatic Metastasis 11/2021
1	Triple Negative Breast Neoplasms 08/2021
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

76	Complement System Proteins (Complement)IBA 01/2022 - 03/2003
21	Complement Inactivating AgentsIBA 08/2021 - 01/2007
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2005
13	Complement C4b-Binding ProteinIBA 11/2016 - 11/2005
12	AntibodiesIBA 01/2022 - 10/2007
11	Complement Factor H (Factor H)IBA 01/2020 - 09/2005
8	Cartilage Oligomeric Matrix ProteinIBA 11/2021 - 12/2010
8	Fibrinogen (Factor I)FDA Link 11/2020 - 03/2007
7	AutoantibodiesIBA 01/2022 - 02/2010
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2007
6	Immunoglobulin G (IgG)IBA 01/2020 - 10/2007
5	Biomarkers (Surrogate Marker)IBA 11/2021 - 12/2013
5	VaccinesIBA 02/2011 - 05/2005
4	LigandsIBA 01/2022 - 03/2003
4	Complement Factor I (C3b Inactivator)IBA 01/2021 - 01/2008
4	Monoclonal AntibodiesIBA 01/2020 - 10/2013
3	Insulin (Novolin)FDA Link 01/2022 - 05/2014
3	Protein Isoforms (Isoforms)IBA 01/2022 - 07/2009
3	Messenger RNA (mRNA)IBA 08/2021 - 11/2009
3	CytokinesIBA 01/2020 - 09/2005
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2019 - 06/2013
3	AsparagineIBA 01/2018 - 10/2007
3	Polysaccharides (Glycans)IBA 01/2018 - 10/2007
3	Peptide Hydrolases (Proteases)FDA Link 10/2016 - 06/2007
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 10/2016 - 08/2009
3	AnticoagulantsIBA 01/2016 - 08/2012
3	LectinsIBA 05/2014 - 02/2011
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2020
2	AntigensIBA 01/2020 - 02/2011
2	Rituximab (Mabthera)FDA Link 01/2020 - 12/2013
2	Complement C3 (C3 Complement)IBA 01/2020 - 01/2019
2	ofatumumab FDA Link 01/2020 - 12/2013
2	anti-dsDNA autoantibodyIBA 01/2020 - 12/2017
2	VitronectinIBA 01/2018 - 08/2009
2	Acetylglucosaminidase (NAGase)IBA 01/2018 - 06/2013
2	Aggrecans (Aggrecan)IBA 10/2016 - 01/2013
2	EpitopesIBA 04/2016 - 01/2005
2	Protein SIBA 01/2016 - 06/2006
2	Complement 3d Receptors (Complement Receptor 2)IBA 09/2014 - 03/2003
2	Serine Proteases (Serine Protease)IBA 05/2014 - 06/2009
2	serglycinIBA 01/2013 - 02/2011
2	Annexin A2 (Annexin II)IBA 09/2012 - 02/2010
2	CollagenIBA 08/2011 - 10/2010
2	FibromodulinIBA 04/2007 - 09/2005
1	OspC proteinIBA 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	1-oleoyl-2-stearoylphosphatidylcholineIBA 01/2022
1	Complement C4 (Complement Component 4)IBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 08/2021
1	Kallikreins (Kallikrein)IBA 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	PrekallikreinIBA 01/2021
1	KininsIBA 01/2021
1	fibrin fragment D (D-dimer)IBA 01/2021
1	complement C3d,gIBA 01/2021

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 08/2021 - 01/2005
2	Immunotherapy 01/2020 - 01/2020
2	Therapeutics 01/2020 - 11/2016